Tag: trial

SAN FRANCISCO, June 07, 2026 (GLOBE NEWSWIRE) -- On May 12, the Science x AI Summit 2026 held in Silicon Valley brought together numerous scientists, AI researchers, and industry institutions. Lim Meng Hoong, founder of MengHoong Intelligent Investment Academy, was invited to participate in the summit and engaged in discussions on the long-term impact of AI on scientific research systems and industrial structures. Unlike previous discussions centered on commercial applications, the summit this year placed greater emphasis on “how AI can drive scientific breakthroughs” and continued to advance international discussions around AI for Science.

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.^2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),² and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).⁴ Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.^5,6

Copenhagen, Denmark, 7 June 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today presented key Phase 1 and preclinical data for AT7687 at the 2026 Scientific Sessions of the American Diabetes Association^®, held in New Orleans, Louisiana from June 5-8, 2026.